The Clinical Effects of Tranilast on Restenosis after Percutaneous Transluminal Coronary Angioplasty.
10.4070/kcj.2001.31.12.1274
- Author:
Woo Kon JEONG
1
;
Myung Ho JEONG
;
Kye Hun KIM
;
Im Kwan JHU
;
Sang Rok LEE
;
Ok Young PARK
;
Ju Hyup YUM
;
Won KIM
;
Ju Han KIM
;
Jae Young RHEW
;
Young Keun AHN
;
Young Chull KIM
;
Jeong Gwan CHO
;
Jong Chun PARK
;
Jung Chaee KANG
Author Information
1. The Heart Center, Chonnam National University Hospital, The Research Institute of Medical Sciences, Kwang Ju, Korea. myungho@chollian.net
- Publication Type:Original Article
- Keywords:
Tranilast;
Restenosis;
Coronary disease;
Angioplasty, transluminal, percutaneous coronary
- MeSH:
Administration, Oral;
Angioplasty, Balloon, Coronary*;
Coronary Disease;
Cytokines;
Follow-Up Studies;
Humans;
Interleukin-1beta;
Jeollanam-do;
Liver Diseases;
Phenobarbital;
Platelet-Derived Growth Factor;
Prospective Studies
- From:Korean Circulation Journal
2001;31(12):1274-1280
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND AND OBJECTIVES: Tranilast is an anti-allergic drug that suppresses the release of cytokines, such as platelet-derived growth factor, transforming growth factor-beta and interleukin-1beta. It has recently become known to be effective in the prevention of restenosis following PTCA (percutaneous transluminal coronary angioplasty). SUBJECTS AND METHODS: One hundred forty two consecutive patients with angina who underwent PTCA between Jan 1999 and Jul 2000 at Chonnam National University Hospital were analyzed prospectively. Thirty patients (Tranilast group:60.8+/-7.7 years, M:F=22:8, 41 lesions) out of 48 who received 300 mg tranilast for 3 months following PTCA and who underwent follow-up CAG (coronary angiogram), were compared with 61 patients (Control group:58.1+/-11.0 years, M:F=52:9, 82 lesions) out of 94, 94 who did not receive tranilast but did undergo follow-up CAG. RESULTS: The restenosis rate per lesion was significantly lower in the Tranilast group than in the Control group on the 6-month follow-up CAG (Tranilast vs. Control group:19.5% vs. 40.2%, p=0.021). The minimal luminal diameter was significantly larger in the Tranilast group as compared to the Control group (1.99+/-0.76 vs. 1.50+/-0.83 mm p=0.002). One patient of the Tranilast group suffered from liver dysfunction and stopped medication. CONCLUSION: The oral administration of tranilast is safe and effective in the prevention of restenosis following PTCA in patients with angina.
